Pharmacokinetic and safety analyses of tenofovir and tenofovir- emtricitabine vaginal tablets in pigtailed macaques

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2665-2674

  Pereira, Lara E ^a   Clark, Meredith R ^b   Friend, David R ^b   Garber, David A ^c   McNicholl, Janet M ^c   Hendry, R Michael ^c   Doncel, Gustavo F ^b   Smith, James M ^c  

^a LifeSource Biomedical LLC Moffett Field   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EMTRICITABINE; TENOFOVIR; ADENINE; DEOXYCYTIDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOPSY; CONTROLLED STUDY; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; GEL; MACACA NEMESTRINA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PLASMA; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA DISCHARGE; VAGINA FLORA; VAGINAL SECRETION; VAGINAL TABLET; ANALOGS AND DERIVATIVES; ANIMAL; INTRAVAGINAL DRUG ADMINISTRATION; MACACA;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ANIMALS; DEOXYCYTIDINE; FEMALE; MACACA; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84898636351     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02336-13     Document Type: Article

References (38)

1. UNAIDS. 2010. UNAIDS report on the global AIDS epidemic 2010. UNAIDS, Geneva, Switzerland. http://www.unaids.org/globalreport/global-report.htm.
2. Voelker R. 2005. Women shoulder growing HIV/AIDS burden. JAMA 293:281-282. http://dx.doi.org/10.1001/jama.293.3.281.
3. Hladik F, Hope TJ. 2009. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6:20-28. http://dx.doi.org/10.1007/s11904-009-0004-1.
4. Hladik F, McElrath MJ. 2008. Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8:447-457. http://dx.doi.org/10.1038/nri2302.
5. Abdool Karim Q, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention ofHIVinfection inwomen.Science 329:1168-1174. http://dx.doi.org/10.1126/science. 1193748.
6. Microbicide Trials Network. 2011. Microbicide Trials Network statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3619.
7. Microbicide Trials Network. 2011. Microbicide Trials Network statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3909.
8. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. 2012. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26:F13-F19. http://dx.doi.org/10.1097/QAD.0b013e3283522272.
9. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team. 2012. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410. http://dx.doi.org/10.1056/ NEJMoa1108524.
10. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367:423-434. http://dx.doi.org/10.1056/NEJMoa1110711.
11. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D, FEM-PrEP Study Group. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-422. http://dx.doi.org/10.1056/ NEJMoa1202614.
12. Microbicide Trials Network. 2013. Daily HIV prevention approaches didn't work for African women in the VOICE study. http://www.mtnstopshiv.org/node/4877.
13. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. 2013. Adherence support approaches in biomedical HIV prevention trials: experiences, insights, and future directions from four multisite prevention trials. AIDS Behav. 17:2143-2155. http://dx.doi.org/10.1007/s10461-013-0429-9.
14. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba ADM. 2011. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 3:112re4. http://dx.doi.org/10.1126/scitranslmed.3003174.
15. Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, Mwafulirwa L, Khumalo-Sakutukwa G, Celentano DD. 2004. Acceptability of a microbicide among women and their partners in a 4-country phase I trial. Am. J. Public Health 94:1159-1164. http://dx.doi.org/10.2105/AJPH.94.7.1159.
16. Bentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, Mayer KH. 2000. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam. Plann. Perspect. 32: 184-188. http://dx.doi.org/10.2307/2648235.
17. Hammett TM, Mason TH, Joanis CL, Foster SE, Harmon P, Robles RR, Finlinson HA, Fuedo R, Vining-Bethea S, Jeter G, Mayer KH, Doherty-Iddings P, Seage GR. 2000. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex. Transm. Dis. 27:119-126. http://dx.doi.org/10.1097/00007435- 200002000-00011.
18. US Department of Health and Human Services. 2010. Guide for the care and use of laboratory animals. US Department of Health and Human Services, Washington, DC.
19. Gunawardana M, Moss JA, Smith TJ, Kennedy S, Kopin E, Nguyen C, Malone AM, Rabe L, Schaudinn C, Webster P, Srinivasan P, Sweeney ED, Smith JM, Baum MM. 2011. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J. Med. Microbiol. 60: 828-837. http://dx.doi.org/10.1099/jmm.0. 028225-0.
20. Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl JRB, Jr, Smith J, Kiser PF. 2012. Safe and sustained delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob. Agents Chemother. 56:1291-1299. http://dx.doi.org/10.1128/AAC.05721-11.
21. Patton DL, Sweeney YC, Rabe LK, Hillier SL. 1996. The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem. Sex. Transm. Dis. 23:489-493. http://dx.doi.org/10.1097/00007435- 199611000-00009.
22. Joglekar NS, Joshi SN, Navlakha SN, Katti UR, Mehendale SM. 2006. Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India-phase I study. Indian J. Med. Res. 123:547-552.
23. Joshi SN, Dutta S, Kumar BK, Katti U, Kulkarni S, Risbud A, Mehendale S. 2008. Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report. Sex. Transm. Infect. 84:343-347. http://dx.doi.org/10.1136/sti.2007.029207.
24. Joshi SN, Katti U, Godbole S, Bharucha KBKK, Kulkarni S, Risbud A, Mehendale S. 2005. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India. Trans. R. Soc. Trop. Med. Hyg. 99:769-774. http://dx.doi.org/10.1016/j.trstmh.2005.01.007.
25. Dobard C, Sharma S, Martin A, Pau CP, Holder A, Kuklenyik Z, Lipscomb J, Hanson DL, Smith J, Novembre FJ, García-Lerma JG, Heneine W. 2012. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissues. J. Virol. 86:718-725. http://dx.doi.org/10.1128/JVI.05842-11.
26. Van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC. 1996. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
27. Srinivas RV, Fridland A. 1998. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymeth-ylcarbonyl) PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob. Agents Chemother. 42:1484-1487.
28. Ebadi MS. 2008. Desk reference of clinical pharmacology, 2nd ed. Taylor and Francis Group, LLC, Boca Raton, FL.
29. Saag MS. 2006. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin. Infect. Dis. 42:126-131. http://dx.doi.org/10.1086/498348.
30. Schinazi RF, Lloyd RMJ, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bamzi HZ, Mellors JW. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881. http://dx.doi.org/10.1128/AAC.37.4. 875.
31. Schinazi RF, McMillan A, Cannon D, Mathis R, Lloyd RM, Peck A, Sommadossi JP, Clair MS, Wilson J, Furman PA, Painter G, Choi W-B, Liotta DC. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431. http://dx.doi.org/10.1128/AAC.36.11. 2423.
32. Nuttall J, Kashuba A, Wang R, White N, Allen P, Roberts J, Romano J. 2012. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob. Agents Chemother. 56:103-109. http://dx.doi.org/10.1128/AAC.00597-11.
33. Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau C-P, Heneine W, Garcia-Lerma JG. 2012. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One 7:e50632. http://dx.doi.org/10.1371/journal.pone.0050632.
34. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83:10358-10365. http://dx.doi.org/10.1128/JVI.01073-09.
35. FDA. 16 July 2012, posting date. FDA approves first drug for reducing the risk of sexually acquired HIV infection (press release). FDA, Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
36. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutskey LA, Wolner-Hanssen P, Holmes KK. 1996. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J. Infect. Dis. 174:1058-1063. http://dx.doi.org/10.1093/infdis/174.5.1058.
37. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. 2006. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir. Ther. 11:377-384.
38. Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskia ES, Borroto-Esoda K, Miller MD. 2009. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6:44. http://dx.doi.org/10.1186/1742- 4690-6-44.